Abstract
Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Current Pharmaceutical Design
Title: Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Volume: 17 Issue: 14
Author(s): Sophia Achab and Yasser Khazaal
Affiliation:
Keywords: Pathological gambling, drugs, antidepressant, lithium, valproate, carbamazepine, naltrexone, nalmefene, topiramate, glutamate, N-acetylcysteine, gambling, antiepileptic, nefazodone, fluvoxamine, paroxetine, sertraline, cyclothymia, olanzapine
Abstract: Given the rates of pathological gambling and its impact on affected individuals and their relatives, effective treatments are needed. There are, however, no approved pharmacological treatments for pathological gambling. This paper describes the development of pharmacological treatments for pathological gambling and is based on a review of the literature published in the past 10 years. Important studies were carried-out on antidepressants, mood stabilizers, and antipsychotic agents. In the absence of comorbid psychiatric disorder, these studies did not conclude to the efficacy of these psychotropic drugs. A possible efficacy of opiate antagonist treatment for pathological gambling has been replicated in a number of placebo-controlled studies. Preliminary results on N-acetyl cysteine, Memantine and Topiramate produced significant improvement for pathological gamblers and may open new avenues for treatment.
Export Options
About this article
Cite this article as:
Achab Sophia and Khazaal Yasser, Psychopharmacological Treatment in Pathological Gambling: A Critical Review, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150774
DOI https://dx.doi.org/10.2174/138161211796150774 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Dual Binding Site Acetylcholinesterase Inhibitors to Multi-Target-Directed Ligands (MTDLs): A Step Forward in the Treatment of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study
Current Alzheimer Research Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) The Perils of Alzheimers Drug Development
Current Alzheimer Research Exploring the Role of Gene Therapy for Neurological Disorders
Current Gene Therapy Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Glutamate and Schizophrenia: Pathophysiology and Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Multicenter Randomized Controlled Trial for the Treatment of Ulcerative Colitis with a Leukocytapheresis Column
Current Pharmaceutical Design Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Structural and Functional MRI in Mild Cognitive Impairment
Current Alzheimer Research Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Memory Improvement with Docosahexaenoic Acid Study (MIDAS)-Brief Review
Current Alzheimer Research Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design